[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201909083UA - Piperidines as covalent menin inhibitors - Google Patents

Piperidines as covalent menin inhibitors

Info

Publication number
SG11201909083UA
SG11201909083UA SG11201909083UA SG11201909083UA SG 11201909083U A SG11201909083U A SG 11201909083UA SG 11201909083U A SG11201909083U A SG 11201909083UA SG 11201909083U A SG11201909083U A SG 11201909083UA
Authority
SG
Singapore
Prior art keywords
international
ann arbor
menin
piperidines
covalent
Prior art date
Application number
Inventor
Shaomeng Wang
Angelo Aguilar
Shilin Xu
Liyue Huang
Jeanne Stuckey
Xu Tianfeng
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of SG11201909083UA publication Critical patent/SG11201909083UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1 (54) Title: PIPERIDINES AS COVALENT MENIN INHIBITORS IN ir) R id Ot 1 R1° en N1 ) , GC R 8b ''''''' . - 71 'R i j e V r1 N Il A 0 .... 1 . 5 ° R8a o x, z2 (I) (57) : The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R la , R ib R ic , R id , R 2 , R , R 3 8a , R , R 8b 10 , m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer. (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PC T oimiolo VIII °nolo III OH H ioo Imo oimIE (10) International Publication Number WO 2018/183857 Al (51) International Patent Classification: A61K 31/445 (2006.01) C07D 401/06 (2006.01) C07D 211/26 (2006.01) (21) International Application Number: PCT/US2018/025417 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/479,520 31 March 2017 (31.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; Office of Technology Trans- fer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109-2590 (US). (72) Inventors: WANG, Shaomeng; 3336 Stirling Ct., Superi- or Township, MI 48198 (US). AGUILAR, Angelo; 2364 Stone Rd., Ann Arbor, MI 48105 (US). XU, Shilin; 3578 Green Brier Blvd., Apartment 405C, Ann Arbor, MI 48105 (US). HUANG, Liyue; 3170 Otter Creek Ct., Ann Arbor, MI 48105 (US). STUCKEY, Jeanne; 13536 Lakebrook Drive, Fenton, MI 48430 (US). TIANFENG, Xu; 2153 Ar- bor Circle West, Apartment 205, Ypsilanti, MI 48197 (US). (74) Agent: NAPOLI, James, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Wills Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 2 I (3)) C
SG11201909083U 2017-03-31 2018-03-30 Piperidines as covalent menin inhibitors SG11201909083UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479520P 2017-03-31 2017-03-31
PCT/US2018/025417 WO2018183857A1 (en) 2017-03-31 2018-03-30 Piperidines as covalent menin inhibitors

Publications (1)

Publication Number Publication Date
SG11201909083UA true SG11201909083UA (en) 2019-10-30

Family

ID=63677047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909083U SG11201909083UA (en) 2017-03-31 2018-03-30 Piperidines as covalent menin inhibitors

Country Status (13)

Country Link
US (1) US11045448B2 (en)
EP (1) EP3600313A4 (en)
JP (1) JP2020515571A (en)
KR (1) KR20190133224A (en)
CN (1) CN110636843A (en)
AU (1) AU2018243586A1 (en)
BR (1) BR112019020130A2 (en)
CA (1) CA3058448A1 (en)
EA (1) EA201992320A1 (en)
IL (1) IL269542A (en)
MX (1) MX2019011412A (en)
SG (1) SG11201909083UA (en)
WO (1) WO2018183857A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6991585B2 (en) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Piperidine as a menin inhibitor
CN111936465A (en) * 2018-03-30 2020-11-13 密歇根大学董事会 Piperidine compounds as covalent MENIN inhibitors
MX2021003732A (en) 2018-10-03 2021-08-11 Univ Michigan Regents Small molecule menin inhibitors.
MX2021007925A (en) 2018-12-31 2021-10-26 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction.
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
TW202204334A (en) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin inhibitors and methods of use for treating cancer
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
US20240124467A1 (en) * 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
US12018032B2 (en) 2021-08-20 2024-06-25 Biomea Fusion, Inc. Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7450898A (en) 1997-05-28 1998-12-30 Tokyo Tanabe Company Limited Indole compounds
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US8242078B2 (en) 2006-10-19 2012-08-14 The University Of Chicago Therapeutics to inhibit MLL-menin interaction for treating leukemia
CA2773131C (en) 2009-09-04 2015-07-14 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
CN103874686B (en) * 2011-05-09 2016-08-17 福马Tm有限责任公司 For suppressing piperidine derivative and the compositions of nicotinamide phosphoribosyl transferase (NAMPT)
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
JP2016512514A (en) 2013-03-13 2016-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions containing thienopyrimidine and thienopyridine compounds and methods for their use
US9212180B2 (en) 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
WO2014200479A1 (en) 2013-06-12 2014-12-18 The Regents Of The University Of Michigan Menin-mll inhibitors and methods of use thereof
US10246464B2 (en) * 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (en) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 Methods and compositions for inhibiting the interaction of menin and mll proteins
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
RU2018126774A (en) 2015-12-22 2020-01-23 Витэ Фармасьютикалз, Инк. MENIN-MLL INTERACTION INHIBITORS
KR102419524B1 (en) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. Cross-linked bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
JP6991585B2 (en) * 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Piperidine as a menin inhibitor
EP3468966B1 (en) 2016-06-10 2020-08-05 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
PL3512850T3 (en) 2016-09-16 2023-10-09 Vitae Pharmaceuticals, Llc Inhibitors of the menin-mll interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
CN110691779B (en) 2017-03-24 2023-10-10 库拉肿瘤学公司 Method for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
CN113164443A (en) 2018-09-26 2021-07-23 库拉肿瘤学公司 Treatment of hematologic malignancies with multiple endocrine oncostatin inhibitors
MX2021007925A (en) 2018-12-31 2021-10-26 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction.
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction

Also Published As

Publication number Publication date
KR20190133224A (en) 2019-12-02
EA201992320A1 (en) 2020-04-22
US20200022953A1 (en) 2020-01-23
AU2018243586A1 (en) 2019-10-17
IL269542A (en) 2019-11-28
BR112019020130A2 (en) 2020-04-22
WO2018183857A1 (en) 2018-10-04
EP3600313A4 (en) 2020-09-23
CA3058448A1 (en) 2018-10-04
CN110636843A (en) 2019-12-31
EP3600313A1 (en) 2020-02-05
JP2020515571A (en) 2020-05-28
MX2019011412A (en) 2020-02-07
US11045448B2 (en) 2021-06-29

Similar Documents

Publication Publication Date Title
SG11201909083UA (en) Piperidines as covalent menin inhibitors
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201808729WA (en) Bet protein degraders
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201804934PA (en) Novel Compounds
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201906883SA (en) Methods for the administration of certain vmat2 inhibitors
SG11201901251SA (en) Aminopyrimidines as alk inhibitors
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808728QA (en) Mdm2 protein degraders
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201907023UA (en) Method of reducing neutropenia
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201906222WA (en) Jak1 selective inhibitors
SG11201909429VA (en) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto